Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Metabolic Solutions Development Company

Latest From Metabolic Solutions Development Company

Cirius Suspects Insulin Resistance Is Underlying Key To NASH

The former Octeta is expanding the ongoing Phase IIb study of its second-generation insulin sensitizer. An insulin sensitizer with a better safety profile than first-generation drugs like Actos may provide a backbone therapy for NASH, the company believes.

Financing Clinical Trials

With Phase III NASH Endpoints In Place, Intercept May Reach Market By 2018

Although it is the first company to reach Phase III in non-alcoholic steatohepatitis, Intercept has a long road ahead with a 2,500-patient trial that will include a 72-week interim look that could lead to initial approval in the U.S. and EU.

BioPharmaceutical United States

MSDC avoids the glitazone as PhIIb insulin sensitiser dances toward partners

The private US firm Metabolic Solutions Development Company (MSDC) has presented Phase IIb data for its insulin sensitiser drug candidate that it says has a novel metabolic action that should avoid the side-effects that have damaged the glitazone drug class.

Metabolic Disorders Neurology

Metabolic Solutions Development Co. LLC

Metabolic Solutions Development thinks it knows why diabetes drugs directed against PPAR-γ ran into safety problems. The start-up is leveraging insights about what not to do, as it works to create an insulin sensitizer that lowers blood glucose levels without increasing white fat and without causing dangerous side effects.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals